Tracers / [68Ga]TacsBOMB6
[68Ga]TacsBOMB6
Also written as [Ga-68]Ga-TacsBOMB6
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- GRPR-targeting bombesin(7-14) peptide derivative
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) antagonist PMID 35744904
- Clinical application
- PET imaging and targeted radioligand therapy of GRPR-expressing solid cancers (e.g., prostate cancer, PC-3 tumor model) PMID 35744904
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | TacsBOMB6 | 35744904 2022 Molecules |
Need this precursor?We can point you to suppliers for [68Ga]TacsBOMB6, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35744904. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35744904: 'TacsBOMB2, TacsBOMB3, TacsBOMB4, TacsBOMB5, and TacsBOMB6'.